Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Neurological disorders (NDs) like Alzheimer's, Parkinson's, and stroke lack effective treatments.
• Stilbenes, natural polyphenols, exhibit neuroprotective properties.
• Resveratrol, piceatannol, and pterostilbene are key stilbenes with potential therapeutic benefits.

Purpose of the Study:

• To explore the neuroprotective potential of stilbenes in neurological disorders.
• To review preclinical and clinical evidence for stilbene efficacy.
• To highlight the need for further clinical research on stilbenes for NDs.

Main Methods:

• Review of preclinical studies on stilbene mechanisms in neurodegeneration.
• Analysis of clinical trial data on stilbene supplementation for brain health.
• Examination of cellular pathways regulated by stilbenes, including oxidative stress, neurogenesis, and mitochondrial function.

Main Results:

• Preclinical data strongly support stilbenes' ability to regulate neurodegeneration pathways.
• Resveratrol demonstrates benefits in reducing oxidative damage and enhancing brain function.
• Clinical studies on resveratrol yield mixed results, indicating a need for more research.

Conclusions:

• Stilbenes show promise as neuroprotective agents for neurological disorders.
• Current clinical evidence for stilbenes is limited, particularly for compounds beyond resveratrol.
• More comprehensive and targeted clinical research is essential to establish therapeutic efficacy in specific patient populations.